Effects of recombinant human prolactin on breast milk composition

Camille E. Powe, Karen M. Puopolo, David S. Newburg, Bo Lönnerdal, Ceng Chen, Maureen Allen, Anne Merewood, Susan Worden, Corrine K. Welt

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVE: The objective of this study was to determine the impact of recombinant human prolactin (r-hPRL) on the nutritional and immunologic composition of breast milk. METHODS: We conducted 2 trials of r-hPRL treatment. In the first study, mothers with documented prolactin deficiency were given r-hPRL every 12 hours in a 28-day, open-label trial. In the second study, mothers with lactation insufficiency that developed while they were pumping breast milk for their preterm infants were given r-hPRL daily in a 7-day, double-blind, placebo-controlled trial. Breast milk characteristics were compared before and during 7 days of treatment. RESULTS: Among subjects treated with r-hPRL (N = 11), milk volumes (73±36 to 146±54 mL/day; P<.001) and milk lactose levels (155± 15 to 184±8 mmol/L; P=.01) increased, whereas milk sodium levels decreased (12.1±2.0 to 8.3±0.5 mmol/L; P=.02). Milk calcium levels increased in subjects treated with r-hPRL twice daily (2.8±0.6 to 5.0± 0.9 mmol/L; P = .03). Total neutral (1.5 ± 0.3 to 2.5 ± 0.4 g/L; P = .04) and acidic (33 ± 4 to 60 ± 6 mg/L; P = .02) oligosaccharide levels increased in r-hPRL-treated subjects, whereas total daily milk immunoglobulin A secretionwas unchanged. CONCLUSIONS: r-hPRL treatment increased milk volume and induced changes in milk composition similar to those that occur during normal lactogenesis. r-hPRL also increased antimicrobially active oligosaccharide concentrations. These effects were achieved for women with both prolactin deficiency and lactation insufficiency.

Original languageEnglish (US)
JournalPediatrics
Volume127
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Human Milk
Prolactin
Milk
Oligosaccharides
Lactation
Mothers
Calcium Carbonate
Lactose
Premature Infants
Immunoglobulin A
Therapeutics
Sodium
Placebos

Keywords

  • Breastfeeding
  • Neonate
  • Nutrition
  • Premature
  • Prolactin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Powe, C. E., Puopolo, K. M., Newburg, D. S., Lönnerdal, B., Chen, C., Allen, M., ... Welt, C. K. (2011). Effects of recombinant human prolactin on breast milk composition. Pediatrics, 127(2). https://doi.org/10.1542/peds.2010-1627

Effects of recombinant human prolactin on breast milk composition. / Powe, Camille E.; Puopolo, Karen M.; Newburg, David S.; Lönnerdal, Bo; Chen, Ceng; Allen, Maureen; Merewood, Anne; Worden, Susan; Welt, Corrine K.

In: Pediatrics, Vol. 127, No. 2, 02.2011.

Research output: Contribution to journalArticle

Powe, CE, Puopolo, KM, Newburg, DS, Lönnerdal, B, Chen, C, Allen, M, Merewood, A, Worden, S & Welt, CK 2011, 'Effects of recombinant human prolactin on breast milk composition', Pediatrics, vol. 127, no. 2. https://doi.org/10.1542/peds.2010-1627
Powe CE, Puopolo KM, Newburg DS, Lönnerdal B, Chen C, Allen M et al. Effects of recombinant human prolactin on breast milk composition. Pediatrics. 2011 Feb;127(2). https://doi.org/10.1542/peds.2010-1627
Powe, Camille E. ; Puopolo, Karen M. ; Newburg, David S. ; Lönnerdal, Bo ; Chen, Ceng ; Allen, Maureen ; Merewood, Anne ; Worden, Susan ; Welt, Corrine K. / Effects of recombinant human prolactin on breast milk composition. In: Pediatrics. 2011 ; Vol. 127, No. 2.
@article{cf410b1f70e04ba2a396fb9419d5cdd9,
title = "Effects of recombinant human prolactin on breast milk composition",
abstract = "OBJECTIVE: The objective of this study was to determine the impact of recombinant human prolactin (r-hPRL) on the nutritional and immunologic composition of breast milk. METHODS: We conducted 2 trials of r-hPRL treatment. In the first study, mothers with documented prolactin deficiency were given r-hPRL every 12 hours in a 28-day, open-label trial. In the second study, mothers with lactation insufficiency that developed while they were pumping breast milk for their preterm infants were given r-hPRL daily in a 7-day, double-blind, placebo-controlled trial. Breast milk characteristics were compared before and during 7 days of treatment. RESULTS: Among subjects treated with r-hPRL (N = 11), milk volumes (73±36 to 146±54 mL/day; P<.001) and milk lactose levels (155± 15 to 184±8 mmol/L; P=.01) increased, whereas milk sodium levels decreased (12.1±2.0 to 8.3±0.5 mmol/L; P=.02). Milk calcium levels increased in subjects treated with r-hPRL twice daily (2.8±0.6 to 5.0± 0.9 mmol/L; P = .03). Total neutral (1.5 ± 0.3 to 2.5 ± 0.4 g/L; P = .04) and acidic (33 ± 4 to 60 ± 6 mg/L; P = .02) oligosaccharide levels increased in r-hPRL-treated subjects, whereas total daily milk immunoglobulin A secretionwas unchanged. CONCLUSIONS: r-hPRL treatment increased milk volume and induced changes in milk composition similar to those that occur during normal lactogenesis. r-hPRL also increased antimicrobially active oligosaccharide concentrations. These effects were achieved for women with both prolactin deficiency and lactation insufficiency.",
keywords = "Breastfeeding, Neonate, Nutrition, Premature, Prolactin",
author = "Powe, {Camille E.} and Puopolo, {Karen M.} and Newburg, {David S.} and Bo L{\"o}nnerdal and Ceng Chen and Maureen Allen and Anne Merewood and Susan Worden and Welt, {Corrine K.}",
year = "2011",
month = "2",
doi = "10.1542/peds.2010-1627",
language = "English (US)",
volume = "127",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - Effects of recombinant human prolactin on breast milk composition

AU - Powe, Camille E.

AU - Puopolo, Karen M.

AU - Newburg, David S.

AU - Lönnerdal, Bo

AU - Chen, Ceng

AU - Allen, Maureen

AU - Merewood, Anne

AU - Worden, Susan

AU - Welt, Corrine K.

PY - 2011/2

Y1 - 2011/2

N2 - OBJECTIVE: The objective of this study was to determine the impact of recombinant human prolactin (r-hPRL) on the nutritional and immunologic composition of breast milk. METHODS: We conducted 2 trials of r-hPRL treatment. In the first study, mothers with documented prolactin deficiency were given r-hPRL every 12 hours in a 28-day, open-label trial. In the second study, mothers with lactation insufficiency that developed while they were pumping breast milk for their preterm infants were given r-hPRL daily in a 7-day, double-blind, placebo-controlled trial. Breast milk characteristics were compared before and during 7 days of treatment. RESULTS: Among subjects treated with r-hPRL (N = 11), milk volumes (73±36 to 146±54 mL/day; P<.001) and milk lactose levels (155± 15 to 184±8 mmol/L; P=.01) increased, whereas milk sodium levels decreased (12.1±2.0 to 8.3±0.5 mmol/L; P=.02). Milk calcium levels increased in subjects treated with r-hPRL twice daily (2.8±0.6 to 5.0± 0.9 mmol/L; P = .03). Total neutral (1.5 ± 0.3 to 2.5 ± 0.4 g/L; P = .04) and acidic (33 ± 4 to 60 ± 6 mg/L; P = .02) oligosaccharide levels increased in r-hPRL-treated subjects, whereas total daily milk immunoglobulin A secretionwas unchanged. CONCLUSIONS: r-hPRL treatment increased milk volume and induced changes in milk composition similar to those that occur during normal lactogenesis. r-hPRL also increased antimicrobially active oligosaccharide concentrations. These effects were achieved for women with both prolactin deficiency and lactation insufficiency.

AB - OBJECTIVE: The objective of this study was to determine the impact of recombinant human prolactin (r-hPRL) on the nutritional and immunologic composition of breast milk. METHODS: We conducted 2 trials of r-hPRL treatment. In the first study, mothers with documented prolactin deficiency were given r-hPRL every 12 hours in a 28-day, open-label trial. In the second study, mothers with lactation insufficiency that developed while they were pumping breast milk for their preterm infants were given r-hPRL daily in a 7-day, double-blind, placebo-controlled trial. Breast milk characteristics were compared before and during 7 days of treatment. RESULTS: Among subjects treated with r-hPRL (N = 11), milk volumes (73±36 to 146±54 mL/day; P<.001) and milk lactose levels (155± 15 to 184±8 mmol/L; P=.01) increased, whereas milk sodium levels decreased (12.1±2.0 to 8.3±0.5 mmol/L; P=.02). Milk calcium levels increased in subjects treated with r-hPRL twice daily (2.8±0.6 to 5.0± 0.9 mmol/L; P = .03). Total neutral (1.5 ± 0.3 to 2.5 ± 0.4 g/L; P = .04) and acidic (33 ± 4 to 60 ± 6 mg/L; P = .02) oligosaccharide levels increased in r-hPRL-treated subjects, whereas total daily milk immunoglobulin A secretionwas unchanged. CONCLUSIONS: r-hPRL treatment increased milk volume and induced changes in milk composition similar to those that occur during normal lactogenesis. r-hPRL also increased antimicrobially active oligosaccharide concentrations. These effects were achieved for women with both prolactin deficiency and lactation insufficiency.

KW - Breastfeeding

KW - Neonate

KW - Nutrition

KW - Premature

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=79551538640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551538640&partnerID=8YFLogxK

U2 - 10.1542/peds.2010-1627

DO - 10.1542/peds.2010-1627

M3 - Article

C2 - 21262884

AN - SCOPUS:79551538640

VL - 127

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

ER -